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Vancomycin-resistant enterococci (VRE),
first reported in Europe in 1988, are emerging as
a global threat to public health (1). The incidence
of VRE infection and colonization among hos-
pitalized patients has increased rapidly in the
last 7 years. From 1989, the year VRE was first
identified in the United States, through 1993, the
proportion of enterococcal isolates resistant to
vancomycin reported to the National Nosocomial
Infections Surveillance System increased 20-fold
(2). Infection with VRE may be associated with
increased mortality (3,4), and no effective anti-
microbial therapy is available for many VRE (5,6).
Multiple factors predispose a person to
infection with VRE, but colonization precedes
most infections (7). In the United States, noso-
comial transmission of VRE from patient to
patient has been emphasized (3,7-10). Although
VRE introduced into hospitals by colonized
patients from VRE-endemic settings has been
reported (8,9), it is unclear how VRE is first
introduced into most U.S. hospitals.
Although no data so far support significant
acquisition and transmission of VRE outside the
health-care setting in the United States, a
growing number of reports from Europe suggest
that colonization with VRE frequently occurs in
the community (11-15). Reports from Europe also
have suggested that VRE exist elsewhere in the
environment, including animal feces and human
foods of animal origin (15-23). Additional evi-
dence supports the transmission of VRE to
persons in contact with these sources, resulting
in an increased human reservoir of VRE colo-
nization (15,16,22). If VRE is frequently intro-
duced into health-care settings from community
sources, its control will require community-based
initiatives, unlike measures used to control
nosocomial pathogens.
This review summarizes the existing evi-
dence for community acquisition and transmis-
sion of VRE outside the health-care setting in
Europe, relates these findings to the epidemiology
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of VRE in the United States, discusses steps to
stem community transmission of VRE, and
identifies research needs.
Animal and Community Reservoirs of VRE
in Europe
VRE were first reported outside the health-
care setting in 1993 when vancomycin-resistant
Enterococcus faecium was recovered from waste
water samples collected from sewage treatment
plants in urban areas of England (16) and in
small towns in Germany (17). The following year,
Bates et al. recovered VRE from livestock feces
and from uncooked chicken samples purchased
from retail outlets (18). Klare et al. also have
found VRE in manure samples from pig and
poultry farms in Germany and suggested a pos-
sible relationship between the recovery of these
organisms and the use of avoparcin, a glyco-
peptide antimicrobial drug used as a livestock
feed additive in many European countries (19).
The association between the recovery of VRE
from food animals, especially poultry, and the use
of avoparcin at subtherapeutic doses for growth
promotion has now been confirmed by epide-
miologic studies in Denmark (20,21), Norway
(22), and the Netherlands (15).
The link between VRE colonization of
animals used in food production and human VRE
colonization was first suggested by Bates et al.,
who recovered VRE with identical ribotypes from
retail chicken carcasses and humans (17). VRE
has also been recovered from poultry and pork
collected from slaughterhouses and retail out-
lets in Germany (19,23), Norway (22), and the
Netherlands (15). More recently, a higher pre-
valence of VRE colonization was found among
persons who worked on turkey farms or in turkey
processing plants than among urban residents in
the Netherlands (15). Because of the heteroge-
neity of pulsed-field gel electrophoresis patterns
encountered in each population and the con-
trasting similarity of patterns found between
individual turkey farmer/slaughterer isolates and
animal isolates, the investigators concluded that
“dissemination of VRE from animal origin via the
food chain seems likely” (15).
 The presence of the vanA, vanX, and vanR
genes in VRE isolates examined from the feces of
pigs and poultry in Denmark (21) suggests that a
gene cluster similar to that found on Tn1546, the
transposon responsible for high-level vancomycin
resistance in human isolates (24,25), is responsible
for resistance among these animal isolates.
Regardless of whether individual clones of VRE
are transmitted through the food chain or
whether transfer of a transposable genetic ele-
ment (i.e., Tn1546) from VRE-colonized animals
to humans occurs, evidence points to a similarity
between organisms present in these two popu-
lations and suggests transmission of vanco-
mycin resistance between the microbial flora of
human and animal species.
If VRE from poultry, swine, and other food-
producing animals play a role in human colo-
nization and infection, a significant level of VRE
colonization may be found among persons not
associated with the health-care setting. In
Europe, VRE have been detected among persons
outside the health-care setting in several stu-
dies (11-14). VRE were isolated from the stool of
three (2%) of 184 persons in Oxford, England (11),
7 (17%) of 40 persons living in Charleroi,
Belgium, without recent exposure to a health-
care setting (12), and 22 (3.5%) of 636 patients
cultured within 2 days of entering a hospital in
Belgium (13). A community survey in the
Netherlands performed on 200 outpatient stool
samples submitted from patients with symptoms
of diarrhea demonstrated a prevalence of VRE
colonization of 2%, a rate similar to the 1%-3%
prevalence among hospital inpatients (14). In
another survey, 13 (11%) of 117 urban residents
in the Netherlands harbored VRE (15).
VRE Outside the Health-Care Setting in the
United States
 Human VRE colonization outside the health-
care setting has not been demonstrated in the
United States. No VRE was found in two com-
munity prevalence surveys designed specifically
to detect VRE (26,27). The number of persons
studied, however, remains small (304), and the
culture methods used may not have been the
most sensitive for detecting small numbers of
organisms (26,28).
Other lines of epidemiologic evidence in the
United States support the possible existence of
community VRE transmission. Although several
hospital outbreaks of VRE caused by a limited
number of genetic clones have been reported
(9,26), polyclonal outbreaks have been observed
in other instances (3,10,29,30). Delayed detection
of VRE in the hospital population or the presence
of a highly mobile element such as Tn1546 trans-
mitting vancomycin resistance between genetically313 Vol. 3, No. 3, July–September 1997 Emerging Infectious Diseases
Synopses
dissimilar enterococci could explain this finding.
Another plausible but unproven explanation is
that a larger community reservoir containing
genetically diverse VRE exists. Additional evi-
dence is provided by reports of VRE among
patients in medically isolated communities (i.e.,
isolated population centers served by few inpa-
tient health-care facilities that infrequently receive
outside patient transfers) in the United States
(L.C. McDonald, unpub. data) and the recent
finding of VRE colonization among patients from
the community within the first 24 hours of admis-
sion to a hospital intensive care unit (31). Finally,
the existence of enterococci possessing high-level
resistance to aminoglycosides in a community pre-
valence survey (32) provides evidence that anti-
microbial-resistant enterococci can disseminate
outside health-care settings in the United States.
If community transmission is occurring in
the United States, potential vehicles of such
transmission include human or animal food.
Antimicrobial resistance in enterococci has been
more prevalent in farm animals exposed to
antimicrobial drugs (33,34). Although high-level
aminoglycoside–resistant enterococci have been
recovered from chicken prepared in the cafeteria
of a hospital where VRE was endemic (35),
isolation of VRE with the VanA phenotype from
animals or human foods of animal origin have not
been reported. Recovery of VRE with the VanA
phenotype from dog food sold in the United States
(36) and evidence from Europe suggesting that
VRE may be prevalent in household pets (cats
and dogs) (37, 38) with a genotype common to
both human and pet hosts (37) suggests another
mode of community transmission. Finally, trans-
mission of VRE from a recently discharged patient
to a family member suggests that household con-
tact, including food preparation, may lead to com-
munity transmission in the United States (39).
Implications
If community transmission is important in
the global spread of VRE, factors leading to its
emergence in this setting must be examined, and
measures must be taken to control transmission.
In response to data linking the use of avoparcin
with the emergence of VRE in the food chain and
potential transmission to humans, Denmark
(1995) and Germany (1996) imposed bans on the
use of avoparcin at subtherapeutic doses in food
animals for growth promotion (12,40). This
action by two member states has been followed
recently by a European Union-wide ban on avo-
parcin (41). Avoparcin has never been licensed
for use in the United States or Canada because of
its carcinogenic potential; illegal use, however,
has been reported (42).
Feed additive manufacturers have resisted
proposals to ban the use of avoparcin at sub-
therapeutic doses for food animal growth pro-
motion in Europe (43,44). Opponents of the ban
have suggested that the relatively low incidence
of human VRE infections in European countries
where avoparcin has been used for many years,
compared with the high rate in the United States,
where avoparcin is not used, is inconsistent with
the hypothesis that avoparcin is a major factor in
the emergence of VRE (43). However, profound
differences may exist between the United States
and European countries in the amount of glyco-
peptides used in health-care settings.
Vancomycin use in U.S. hospitals has
increased dramatically in the past 10 to 15 years
(45,46) because of a variety of factors, including
increases in the incidence of methicillin-resistant
staphylococci, prosthetic device–related infec-
tions,  Clostridium difficile colitis, and
inappropriate use of the drug. Although vanco-
mycin and other glycopeptide use in European
health-care settings has not been similarly
documented, this marked increase in human
glycopeptide use is thought to be primarily a U.S.
phenomenon (43). Because the use of vancomycin
and other antimicrobial drugs is an important
risk factor for human VRE infection (3,7), if
glycopeptides were prescribed in European hos-
pitals at levels common in U.S. hospitals, there
might be an even greater incidence of VRE
infections in Europe. Likewise, given the suspected
greater use of glycopeptides in U.S. hospitals, if
community carriage of VRE were to increase in
the United States, there might be an even greater
incidence of VRE infections in U.S. hospitals.
 Although the exact role of human anti-
microbial use in the transmission of VRE is not
known, observations from an animal model (in
which mice were orally administered VRE and
became only transiently colonized unless simul-
taneously exposed to antimicrobials [47]) support
an important role for antimicrobial drugs in
establishing persistent colonization. Antimicro-
bial drugs used in health-care settings may alter
bowel flora, rendering patients more susceptible
to colonization by VRE transmitted from other
colonized or infected patients. Epidemiologic314 Emerging Infectious Diseases Vol. 3, No. 3, July–September 1997
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evidence of foodborne VRE transmission in the
community suggests  that antimicrobial drugs may
predispose hospitalized patients to colonization
with ingested VRE. Contamination of a patient’s
food may occur during consumption by a variety
of mechanisms, including contamination with
VRE from the hands of the patient or health-care
worker. In areas where VRE is also found in the
animal food supply, contamination may also
occur during processing by contact with VRE
from the bowel flora of the food animal.
In addition to predisposing patients to
colonization, some antimicrobial drugs appear to
increase the number of enterococci in the stool
(48) and may therefore increase the number of
VRE in the stool to a level where colonization can
become more readily detected by culture
methods. Either of these effects could explain the
findings of Van der Auwera et al.(49), who
described changes in the bowel flora of 22 healthy
human volunteers in Belgium who were
administered oral glycopeptides (teicoplanin or
vancomycin) for 3 weeks in 1989. None had VRE
recovered from their stool before exposure to the
oral glycopeptide; whereas after such exposure,
VRE was recovered from 64% of the volunteers
(49). Although this detection of VRE may have
represented new colonization from a contami-
nated food supply or
unidentified occupational
risk (e.g., employment
in a health-care setting),
it appears just as pro-
bable that exposure to
glycopeptides selectively
increased the number
of VRE already in the






and animal origins of
VRE. It is clear, however,
that the use of glyco-





and changes in bowel flora. Genetically related
VRE isolates have been found in livestock,
animal carcasses, foods, outpatients, and hospi-
talized patients, strongly suggesting, if not
proving, that interspecies transmission can occur
and may contribute to colonization and infection
in humans. The recovery of genetically similar
isolates at various links along the food chain
suggests that ingestion of the organism is a
plausible mode of such interspecies transmission.
The additional finding that E. faecium (the most
common species of VRE) may better tolerate
exposure to higher temperatures than E. faecalis
makes survival in undercooked foods appear
more plausible (50). After ingestion, factors such
as a high organism load, reduced gastric acidity,
or recent antimicrobial exposure could allow the
organism to more readily establish persistent
colonization in the human large intestine. After a
VRE-colonized person is admitted to a health-
care facility, additional antimicrobial exposure
may enable small numbers of VRE in the large
intestine to selectively increase to a point where
interpatient transmission is promoted, colo-
nization is more readily detected, and clinical
infection is more likely to occur (Figure).
If livestock are an important source of VRE
for humans, reducing the number of colonized
Figure. Potential interaction between community and health-care settings in the
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livestock would be an effective control measure
for limiting VRE infections. Since no therapy
exists to eliminate VRE colonization, a rational
approach would be to reduce selective pressure
for the organism by limiting the use of
glycopeptides. Although no glycopeptides are
approved for use at subtherapeutic doses in food
animals for growth promotion in the United
States, vancomycin has been used therapeutically
in veterinary medicine. However, a prohibition of
extralabel therapeutic use of glycopeptides in
food-producing animals has been announced (51).
Such a ban would appear a reasonable pre-
cautionary measure against transmission of VRE
within and between various animal populations
and would be consistent with existing control
efforts recommended by the Hospital Infection Con-
trol Practices Advisory Committee, which empha-
sizes prudent vancomycin use in humans (52).
The role of community transmission of VRE
both within and between animal and human
populations in Europe and the United States
requires further study. Culture surveys for VRE
among healthy human volunteers who have had
no recent contact with health-care settings
should be performed with sensitive culture
methods. Such surveys should include family
members of recently discharged patients known
to be colonized or infected with VRE. Additional
surveys among animal populations used for food
production in the United States should also be
performed. Finally, additional laboratory inves-
tigations using molecular epidemiologic methods
will be required to confirm or refute present
evidence for transmission of VRE between ani-
mal and human populations. If transmission of
VRE from unrecognized sources can be identified
and controlled, colonization of hospitalized patients
may be reduced, leading to lower rates of noso-
comial infections due to VRE.
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